Non-insulin oral drug(s)-Forxiga (dapagliflozin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Forxiga (dapagliflozin) Posts on Medivizor

Do SGLT2 inhibitors increase the risk of urogenital infections in patients with diabetes?

Do SGLT2 inhibitors increase the risk of urogenital infections in patients with diabetes?

Posted by on Aug 22, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the risk of urogenital infections in patients with diabetes taking sodium-glucose co-transporter 2 (SGLT2) inhibitors. It found that SGLT2 inhibitors increase the risk of urogenital infections in women over 50 years of age, especially in the first month of treatment. Some background SGLT 2 inhibitors such...

Read More

Is liraglutide an effective add-on treatment for poorly controlled type 2 diabetes?

Is liraglutide an effective add-on treatment for poorly controlled type 2 diabetes?

Posted by on Aug 8, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated whether liraglutide (Victoza) improves diabetic control in patients with difficult to control type 2 diabetes (T2D) and if there were certain factors that influence the effects of liraglutide. It found that patients responded equally well to liraglutide regardless of body mass index (BMI; a measurement of...

Read More

Do SGLT2 inhibitors reduce heart disease compared to DPP-4 inhibitors?

Do SGLT2 inhibitors reduce heart disease compared to DPP-4 inhibitors?

Posted by on Jul 26, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effects on heart disease for SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes (T2D). It found that patients using SGLT2 inhibitor medications had lower rates of heart failure, heart attack, and stroke. Some background T2D is a disorder of high levels of glucose (sugar) in the blood. T2D...

Read More

Is the off-label use of type-2 diabetes medications in type 1 diabetes causing increased rates of diabetic ketoacidosis?

Is the off-label use of type-2 diabetes medications in type 1 diabetes causing increased rates of diabetic ketoacidosis?

Posted by on Dec 9, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study examined the frequency of sodium-glucose cotransporter 2 (SGLT2) inhibitor use in type 1 diabetes (T1D) and the resulting rates of diabetic ketoacidosis (DKA). The study concluded that while the proportion of SGLT2 use in T1D is small, there is a significant associated risk of DKA. Some background There are two...

Read More

Can dapagliflozin help improve blood magnesium levels in patients with Type 2 diabetes?

Can dapagliflozin help improve blood magnesium levels in patients with Type 2 diabetes?

Posted by on Nov 6, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study examined the effects of dapagliflozin (Forxiga) on blood magnesium levels in patients with type 2 diabetes (T2D). The authors concluded that dapagliflozin treatment helped improve blood magnesium levels in these patients. Some background T2D is associated with a number of other health complications. Patients with T2D...

Read More

Do SGLT2 inhibitors prevent cardiovascular complications in type 2 diabetes?

Posted by on Sep 10, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study investigated whether SGLT2 (sodium-glucose co-transporter-2) inhibitors reduced the risk of cardiovascular complications in patients with type 2 diabetes. They found that SGLT2 inhibitors were associated with reduced risk of cardiovascular disease and mortality compared to other treatment types.  Some background...

Read More